David W. Yaffee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David W. Yaffee has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Eugene A. Grossi
Division of Cardiac Surgery, Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY
12 shared publications - Aubrey C. Galloway
Department of Cardiothoracic Surgery, Division of Cardiac Surgery, NYU Langone Health, New York, NY, USA
7 shared publications - Patricia Ursomanno
Department of Cardiothoracic Surgery, New York University Langone Health, New York, NY 10016, USA
5 shared publications Didier F. Loulmet
Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
4 shared publicationsAbe DeAnda
Departments of Cardiothoracic Surgery
3 shared publicationsAnnette E. Rabinovich
Departments of Cardiothoracic Surgery
3 shared publications
Latest Publications
- 6 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (1)
Early and Intermediate Outcomes of Cavitron Ultrasonic Surgical Aspiration to Treat Mitral Annular Calcification
Objectives: Severe mitral annular calcification (MAC) carries an increased risk of perioperative complications in patients undergoing mitral valve surgery and may be considered a prohibitive surgical risk. Cavitron ultrasonic surgical aspiration (CUSA) has been reported as a method for controlled debridement of severe MAC during mitral valve surgery; however, experience in the literature is limited. Methods: We assessed 30-day and intermediate-term outcomes in 67 consecutive patients (mean age: 72 [SD 9] years; female sex: 65.7% [44/67]) with severe MAC who underwent mitral valve repair or replacement for mitral stenosis and/or regurgitation using CUSA from March 2021 through December 2024. Operations included isolated mitral valve replacement (41.8% [28/67]), isolated mitral valve repair (4.5% [3/67]), mitral and aortic valve replacement (37.3% [25/67]), mitral valve replacement with coronary bypass (6.0% [4/67]), and mitral and aortic valve replacement with coronary bypass (10.4% [7/67]). Intermediate survival was estimated using the Kaplan-Meier method. Results: Mortality rate was 6.0% (4/67), stroke was 3.0% (2/67), and new postoperative atrial fibrillation was 29.0% (20/67). There were no atrioventricular groove ruptures. At a median echocardiographic follow-up time of 361 days (interquartile range [IQR] 112, 671), moderate paravalvular leak occurred in 3.0% (1/67). Mid-term all-cause mortality was 9.0% at a mean follow-up time of 42.5 (95% CI, 39.0, 46.0) months. Conclusions: The use of CUSA to debride severe mitral annular calcification in patients undergoing mitral valve surgery is associated with acceptable short-term morbidity and mortality and durable intermediate-term results. This technique allows surgical intervention in patients who may otherwise be deemed prohibitive surgical risk.
- 6 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (1)
Early and Intermediate Outcomes of Cavitron Ultrasonic Surgical Aspiration to Treat Mitral Annular Calcification
Objectives: Severe mitral annular calcification (MAC) carries an increased risk of perioperative complications in patients undergoing mitral valve surgery and may be considered a prohibitive surgical risk. Cavitron ultrasonic surgical aspiration (CUSA) has been reported as a method for controlled debridement of severe MAC during mitral valve surgery; however, experience in the literature is limited. Methods: We assessed 30-day and intermediate-term outcomes in 67 consecutive patients (mean age: 72 [SD 9] years; female sex: 65.7% [44/67]) with severe MAC who underwent mitral valve repair or replacement for mitral stenosis and/or regurgitation using CUSA from March 2021 through December 2024. Operations included isolated mitral valve replacement (41.8% [28/67]), isolated mitral valve repair (4.5% [3/67]), mitral and aortic valve replacement (37.3% [25/67]), mitral valve replacement with coronary bypass (6.0% [4/67]), and mitral and aortic valve replacement with coronary bypass (10.4% [7/67]). Intermediate survival was estimated using the Kaplan-Meier method. Results: Mortality rate was 6.0% (4/67), stroke was 3.0% (2/67), and new postoperative atrial fibrillation was 29.0% (20/67). There were no atrioventricular groove ruptures. At a median echocardiographic follow-up time of 361 days (interquartile range [IQR] 112, 671), moderate paravalvular leak occurred in 3.0% (1/67). Mid-term all-cause mortality was 9.0% at a mean follow-up time of 42.5 (95% CI, 39.0, 46.0) months. Conclusions: The use of CUSA to debride severe mitral annular calcification in patients undergoing mitral valve surgery is associated with acceptable short-term morbidity and mortality and durable intermediate-term results. This technique allows surgical intervention in patients who may otherwise be deemed prohibitive surgical risk.
- Open Access
- 30 August 2023
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 1 (4) , 631-634
Racial Disparities in Atrial Fibrillation After Coronary Artery Bypass: Impact of Left Atrial Volume
- 30 August 2023
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 1 (4) , 631-634
Open AccessRacial Disparities in Atrial Fibrillation After Coronary Artery Bypass: Impact of Left Atrial Volume
- 1 November 2016
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 152 (5) , e103-e104
Rethinking the gold standard of correction for paravalvular leak: Why correct when you can prevent?
- 1 November 2016
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 152 (5) , e103-e104
Rethinking the gold standard of correction for paravalvular leak: Why correct when you can prevent?
- 19 September 2016
- Published by AME Publishing Company in Public Health and Emergency
- Vol. 1 (5) , 33
Evaluation and management of aerodigestive conditions
More than 250,000 people in the United States are diagnosed with tumors involving the aerodigestive systems yearly. The majority of these malignancies arise from lung cancer, esophageal cancer, and metastatic disease. Unfortunately, these patients frequently present in later stages of their disease due to lack of symptoms in early stages. Consequently, the prognosis is often poor and treatment does not include surgical resection. These patients are often gravely ill and their tumors are life threatening conditions. In the case of esophageal cancer malnutrition and dehydration are common symptoms. In the case of lung cancer or metastatic disease to the airway severe symptoms including respiratory failure, hemoptysis, and obstructive pneumonia frequently occur. Management of these patients is frequently challenging but can be rewarding. Successful management allows for increased treatment options as well as prolonging and improving quality of life. In this manuscript the authors describe management options, various tools and outcomes associated with aerodigestive conditions.
- 19 September 2016
- Published by AME Publishing Company in Public Health and Emergency
- Vol. 1 (5) , 33
Evaluation and management of aerodigestive conditions
More than 250,000 people in the United States are diagnosed with tumors involving the aerodigestive systems yearly. The majority of these malignancies arise from lung cancer, esophageal cancer, and metastatic disease. Unfortunately, these patients frequently present in later stages of their disease due to lack of symptoms in early stages. Consequently, the prognosis is often poor and treatment does not include surgical resection. These patients are often gravely ill and their tumors are life threatening conditions. In the case of esophageal cancer malnutrition and dehydration are common symptoms. In the case of lung cancer or metastatic disease to the airway severe symptoms including respiratory failure, hemoptysis, and obstructive pneumonia frequently occur. Management of these patients is frequently challenging but can be rewarding. Successful management allows for increased treatment options as well as prolonging and improving quality of life. In this manuscript the authors describe management options, various tools and outcomes associated with aerodigestive conditions.
- 1 January 2016
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 28 (4) , 741-747
Cardiovascular Surgery in the Elderly
- 1 January 2016
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 28 (4) , 741-747
Cardiovascular Surgery in the Elderly
- 1 October 2015
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 25 (5) , 420-423
Initial Outcomes of Symmetrically Flared Covered Nitinol Stents for Esophageal Pathologies
A recently available, low profile, fully covered metal stent with symmetrical flares (FCMSF) may offer improved resistance to migration in esophageal disease.A retrospective review of 58 esophageal FCMSF placed in 46 consecutive patients was performed. Pathologies included stricture and leak of benign and malignant etiology.Sixteen of 58 stents (28%) were placed urgently/emergently. All patients had successful stent deployment with 0% stent-related hospital mortality. Postoperative morbidity occurred in 15 of the 58 (26%) stents and included stent migration, atrial fibrillation, pneumonia, pneumothorax, urinary retention, hemodynamic instability, and chronic obstructive pulmonary disease exacerbation. In patients with stricture (n=29), mean dysphagia scores were reduced from 3.1±0.6 preoperatively to 1.1±0.8 postoperatively (P<0.001). For leak, stent therapy (±drainage) avoided formal esophageal operation in 95% (21/22). Four stents (6.9%) were removed for stent migration, 2 of which migrated after adjuvant chemoradiation. Adjuvant chemoradiation therapy was an independent risk factor for stent migration (odds ratio=1.6; P=0.02) by multivariable regression analysis. The mean duration of stent therapy was 65±62 days for stricture (27/34 remain in situ) and 57±57 days for leak (10/22 remain in situ). The median hospital length of stay was 2 days.FCMSF provide a safe and effective therapy for both benign and malignant esophageal dysphagia and leaks. The symmetrical property may contribute to the overall low observed migration rate while still allowing for simple and safe stent retrieval.
- 1 October 2015
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 25 (5) , 420-423
Initial Outcomes of Symmetrically Flared Covered Nitinol Stents for Esophageal Pathologies
A recently available, low profile, fully covered metal stent with symmetrical flares (FCMSF) may offer improved resistance to migration in esophageal disease.A retrospective review of 58 esophageal FCMSF placed in 46 consecutive patients was performed. Pathologies included stricture and leak of benign and malignant etiology.Sixteen of 58 stents (28%) were placed urgently/emergently. All patients had successful stent deployment with 0% stent-related hospital mortality. Postoperative morbidity occurred in 15 of the 58 (26%) stents and included stent migration, atrial fibrillation, pneumonia, pneumothorax, urinary retention, hemodynamic instability, and chronic obstructive pulmonary disease exacerbation. In patients with stricture (n=29), mean dysphagia scores were reduced from 3.1±0.6 preoperatively to 1.1±0.8 postoperatively (P<0.001). For leak, stent therapy (±drainage) avoided formal esophageal operation in 95% (21/22). Four stents (6.9%) were removed for stent migration, 2 of which migrated after adjuvant chemoradiation. Adjuvant chemoradiation therapy was an independent risk factor for stent migration (odds ratio=1.6; P=0.02) by multivariable regression analysis. The mean duration of stent therapy was 65±62 days for stricture (27/34 remain in situ) and 57±57 days for leak (10/22 remain in situ). The median hospital length of stay was 2 days.FCMSF provide a safe and effective therapy for both benign and malignant esophageal dysphagia and leaks. The symmetrical property may contribute to the overall low observed migration rate while still allowing for simple and safe stent retrieval.
- Open Access
- 1 July 2015
- Vol. 4 (4) , 352-354-354
Progressive design concepts in off-pump left ventricular remodeling mitral valve repair devices
- 1 July 2015
- Vol. 4 (4) , 352-354-354
Open AccessProgressive design concepts in off-pump left ventricular remodeling mitral valve repair devices
- 1 June 2015
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 29 (3) , 703-709
Blood Conservation Strategies Can Be Applied Safely to High-Risk Complex Aortic Surgery
- 1 June 2015
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 29 (3) , 703-709
Blood Conservation Strategies Can Be Applied Safely to High-Risk Complex Aortic Surgery
- Open Access
- 1 May 2015
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 149 (5) , 1456-1458
Fluorescence-guided placement of an endoaortic balloon occlusion device for totally endoscopic robotic mitral valve repair
- 1 May 2015
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 149 (5) , 1456-1458
Open AccessFluorescence-guided placement of an endoaortic balloon occlusion device for totally endoscopic robotic mitral valve repair
- 1 December 2014
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 148 (6) , 2787-2794
Systolic anterior motion of the mitral valve: A 30-year perspective
- 1 December 2014
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 148 (6) , 2787-2794
Systolic anterior motion of the mitral valve: A 30-year perspective